Company / Net Income
Sonoma Pharmaceuticals, Inc. Net Income History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$3.5M
FY2026
5-year range
-$5.2M / -$3.5M
FY2022-FY2026
Trend
+28.5%
vs FY2025
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 10 years, ranging from -$14M in FY2019 to $9M in FY2018.
Based on SEC 10-K filings.
-$3M in FY2026.
Improved from -$5M to -$3M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2026, net income increased 28.5% year-over-year.
- Peak net income was recorded in FY2018.
- Lowest net income in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | -$3.5M | +28.5% |
| FY2025 | -$4.8M | +6.1% |
| FY2024 | -$5.2M | -1.3% |
| FY2023 | -$5.1M | -28.8% |
| FY2022 | -$4.0M | -19.4% |
| FY2021 | -$3.3M | +72.0% |
| FY2020 | -$11.8M | +17.7% |
| FY2019 | -$14.3M | -254.5% |
| FY2018 | $9.3M | +191.3% |
| FY2017 | -$10.2M | -23.9% |
As of FY2026 · SEC 10-K · Updated Jun 28, 2026